Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 25;11(12):3588–3595. doi: 10.7150/jca.42338

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

METTL3 is responsible for the aberrant m6A modification and serves as a prognostic factor in PCa. (A) The m6A contents of poly(A) RNAs in clinical PCa tissues compared with corresponding adjacent normal tissues. (B) The m6A contents of poly(A) RNAs in human four PCa cell lines compared with human prostatic epithelial cell (RWPE-1). (C-D) The mRNA levels of METTL3 in PCa tissues and normal prostate tissues were extracted from the Singh prostate dataset (C) and the TCGA database (D). (E) The mRNA and protein levels of METTL3 were detected in clinical PCa tissues compared with corresponding adjacent normal tissues. (F) The mRNA and protein levels of METTL3 in four PCa cell lines compared to human prostatic epithelial cell (RWPE-1). (G) The expression of METTL3 was detected by IHC assays in clinical 84 PCa specimens and 32 adjacent normal specimens. The percentage of staining gradations of METTL3 in clinical PCa specimens and adjacent normal specimens were shown. (H-I) The prognostic significance of METTL3 expression about overall survival (H) and disease-free survival (I) was analyzed using the GEPIA online database.